SARS-CoV-2感染与mRNA COVID-19疫苗接种后的心脏并发症——PCORnet,美国,2021年1月至2022年1月
利用美国40个卫生系统的电子健康记录数据,计算2021年1月1日至2022年1月31日期间≥5岁SARS-CoV-2感染者按性别和年龄组分层的的心脏结局发生率,并与mRNA COVID-19疫苗接种后比较。结果显示,12-17岁男性第二次接种后心脏结局发生率最高,但该组感染后风险是第二次接种后的1.8-5.6倍;所有其他性别年龄组感染后风险也显著高于接种后(RR 2.2-115.2)。
要点
- ≥5岁人群中,SARS-CoV-2感染后心脏结局风险高于mRNA COVID-19疫苗接种后。
- 12-17岁男性第二次接种后心脏结局发生率最高,但感染后风险仍为接种后的1.8-5.6倍。
- 所有其他性别年龄组感染后风险亦显著高于接种后(RR 2.2-115.2)。
核心结论
- 研究结果表明,SARS-CoV-2感染后心脏结局风险高于mRNA COVID-19疫苗接种后,支持≥5岁所有符合条件者继续使用mRNA COVID-19疫苗。
研究设计与样本
- 利用美国40个卫生系统2021年1月1日至2022年1月31日的电子健康记录数据,计算≥5岁SARS-CoV-2感染者按性别和年龄组(5-11、12-17、18-29、≥30岁)分层的心脏结局发生率。
- 计算mRNA COVID-19疫苗(BNT162b2或mRNA-1273)第一剂、第二剂、剂次不明或任意剂次后按性别和年龄组分层的心肌炎及心肌炎或心包炎发生率。
- 计算风险比(RR),比较SARS-CoV-2感染后与mRNA COVID-19疫苗接种后心脏结局的风险。
主要发现
- mRNA COVID-19疫苗接种后心脏结局发生率在12-17岁男性第二次接种后最高。
- 在12-17岁男性中,SARS-CoV-2感染后心脏结局风险是第二次疫苗接种后的1.8-5.6倍。
- 在所有其他性别和年龄组中,SARS-CoV-2感染后心脏结局风险同样显著高于第一剂、第二剂或剂次不明mRNA COVID-19疫苗接种后(RR 2.2-115.2)。
临床怎么用
- 研究结果支持≥5岁所有符合条件者继续使用mRNA COVID-19疫苗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cardiac complications, particularly myocarditis and pericarditis, have been associated with SARS-CoV-2 (the virus that causes COVID-19) infection (1-3) and mRNA COVID-19 vaccination (2-5). Multisystem inflammatory syndrome (MIS) is a rare but serious complication of SARS-CoV-2 infection with frequent cardiac involvement (6). Using electronic health record (EHR) data from 40 U.S. health care systems during January 1, 2021-January 31, 2022, investigators calculated incidences of cardiac outcomes (myocarditis; myocarditis or pericarditis; and myocarditis, pericarditis, or MIS) among persons aged ≥5 years who had SARS-CoV-2 infection, stratified by sex (male or female) and age group (5-11, 12-17, 18-29, and ≥30 years). Incidences of myocarditis and myocarditis or pericarditis were calculated after first, second, unspecified, or any (first, second, or unspecified) dose of mRNA COVID-19 (BNT162b2 [Pfizer-BioNTech] or mRNA-1273 [Moderna]) vaccines, stratified by sex and age group. Risk ratios (RR) were calculated to compare risk for cardiac outcomes after SARS-CoV-2 infection to that after mRNA COVID-19 vaccination. The incidence of cardiac outcomes after mRNA COVID-19 vaccination was highest for males aged 12-17 years after the second vaccine dose; however, within this demographic group, the risk for cardiac outcomes was 1.8-5.6 times as high after SARS-CoV-2 infection than after the second vaccine dose. The risk for cardiac outcomes was likewise significantly higher after SARS-CoV-2 infection than after first, second, or unspecified dose of mRNA COVID-19 vaccination for all other groups by sex and age (RR 2.2-115.2). These findings support continued use of mRNA COVID-19 vaccines among all eligible persons aged ≥5 years.
引用
- Block JP, Boehmer TK, Forrest CB, et al. Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35389977. doi:10.15585/mmwr.mm7114e1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。